Taking over a second chair


Taking over a second chair

01.10.2015 - Novartis Chairman Joerg Reinhardt is taking over as chairman of the Novartis Foundation’s Board of Trustees.

Reinhardt, who holds a Ph.D. in pharmaceutical sciences from German Saarland University, previously served as chairman of the board of management and the executive committee of Bayer HealthCare. Prior to that, he held the position of Chief Operating Officer of Novartis from 2008 to 2010, and as Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. He also served as Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the US from 2000 to 2010, as a member of the supervisory board of MorphoSys from 2001 to 2004, and as a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013.

Reinhardt succeeds Andrin Oswald. Peter Piot of the London School of Hygiene & Tropical Medicine, Rebecca Weintraub of Harvard Medical School, and Mr. Rainer Boehm from Novartis Pharmaceuticals have also been appointed to the foundation’s trustee board. Previous Board members George Gunn and Jean-Marie Lehn stepped down in the past year.


28.09.2015 Munich-based drug developer leon-nanodrugs GmbH has appointed Theron Odlaug as CEO of the company and its newly formed US subsidiary leon-nanodrugs Inc.

© leon-nanodrugs

Odlaug, who holds a Ph.D. in Public Health from the University of Minnesota, comes with 35 years of experience in the biopharmaceutical industry.

Previously, he was Executive Chairman of Cedarburg Pharmaceuticals and Executive Chairman and CEO of Planet Biopharmaceuticals.  From 2008 until 2011, he was President and CEO of CyDex Pharmaceuticals, and prior to that, Managing Partner of EIR Healthcare Advisors and Executive VP of Fujisawa Healthcare.

leon-nanodrugs has also announced the appointment of Anne Burger as Finance Director.


24.09.2015 UK biotech Atopix Therapeutics Limited has a new CMO: Andrew Zambanini joins Atopix as it advances the clinical development of its lead product for the treatment of atopic dermatitis.

© Atopix

Zambanini has a quarter century of experience in the pharmaceutical industry. He has worked with companies such as GlaxoSmithKline, Takeda Global, Novartis and Circassia. At GSK, the dually accredited Clinical Pharmacologist and Pharmaceutical Physician has most recently held the position of Vice President and Medicine Development Leader. He also leads his own medical consultancy company, Zambanini Consulting.

Zambanini is a Member of the Royal College of Physicians of London and a Fellow of the Faculty of Pharmaceutical Medicine.


22.09.2015 Belgian commercial-stage MDx company Biocartis has appointed Hilde Windels as Deputy CEO.

© Biocartis

Windels previously held the role of CFO at Biocartis, a role she now hands over to corporate financier Ewoud Welten. Before joining Biocartis in 2008, Windels was CFO at Pronota, and before that, at Seps Pharma and Devgen.

She is on the board of directors at Erytech and at the life sciences research institute VIB. She was on the board of biotech association Flanders Bio until 2014.


18.09.2015 Autifony Therapeutics Ltd, a pioneering developer of pharmaceutical treatments for hearing disorders, has named John Hutchison as its new Chief Medical Officer. Hutchison will replace erstwhile CMO Peter Harris, who is retiring at the end of September.

© Autifony

Hutchison, who holds a PhD in Neurobiology by the University of Liverpool, joins Autifony from Pfizer, where he was Chief Medical Officer and VP of Clinical Research at Pfizer Neusentis in the UK. Due to his long experience in clinical drug development in both big pharma and the biotech sector he will take over the lead of Autifony’s growing clinical development team that will oversee the evaluation of two different candidate drugs in multiple clinical trials by the end of the year.


16.09.2015 Oxford-based oncology drug developer Physiomics has appointed Mark Middleton to its Scientific Advisory Board. Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford.

© Physiomics

He is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research UK Oxford Centre. He directs the EPCTU and the Cancer Theme of the NIHR Biomedical Research Centre, and leads several clinical trials in the national portfolio. 

Middleton is a member of the International Melanoma Working Group and of the NCRI Melanoma Clinical Studies Group.


14.09.2015 Swedish cancer vaccine play Immunicum AB has hired Linda Barkemo as Director Clinical Operations.

© Immunicum AB

Barkemo comes from a position as Regional Director Northern Europe at CRO Clintec. Previously, the trained nurse was Clinical Trial Manager at Artimplant and was responsible for clinical studies at AstraZeneca and Pfizer. 


10.09.2015 Recently founded EIT Health has found its CEO: Sylvie Bove is taking over the lead of the European healthcare initiative in September.

© EIT Health

Bove has 20 years of experience as a business executive in the life sciences. Originally from France, she has spent many years in Scandinavia at companies such as Coloplast and Ferring Pharmaceuticals. She contributed to the foundation of the Copenhagen Healthtech Cluster. For the last three years, she also held the role of Innovation Officer at Lund University. 

At EIT Health, Bove will take over from Roche’s Ursula Redeker who served as interim CEO since October 2014. 


07.09.2015 In mid-September, Sean Bohen is joining AstraZeneca as Executive VP of Global Medicines Development and CMO. He will be responsible for late-stage development of small molecule meds and biologics.

© AstraZeneca

Previously, the drug development expert with a doctorate in biochemistry and a medical degree served as Senior VP of Early Development at Genentech. Here, he also held a number of positions in early and late-stage development. Before joining Genentech, Bohen was a clinical instructor in oncology at Stanford University School of Medicine, a research associate at the Howard Hughes Medical Institute and a postdoctoral fellow at the National Cancer Institute.


17.08.2015 George Gunn is the newest member of the board of Pharmaq Holding AS, a Norway-based leader in pharmaceuticals for the aquaculture industry.

© Pharmaq

Gunn has an extensive background in animal health and has recently retired from Novartis AG. At Novartis, the born Scotsman started in 2003 as Head of Animal Health, North America. He went on to head Novartis Animal Health from 2004 until 2015, when the division was sold to Elanco. Prior to joining Novartis, Gunn served as President of Pharmacia Animal Health for three years.

Gunn received the Honorary Degree of Doctor of Veterinary Medicine and Surgery from the University of Edinburgh in 2008. This year, he received a Lifetime Achievement award from the International Federation of Animal Health for his services to the animal health sector.


26.08.2015 In August, Thomas Bachmann has taken over the role of CEO at Eppendorf Group. Bachmann has been a member of the Supervisory Board of the German laboratory product and service provider since 2013.

© Eppendorf AG

Bachmann has been active in the Life Sciences for ten years. Before switching to Eppendorf, he was President of the Bruker BioSpin Group. Prior to that, he was responsible for the Switzerland-based Tecan Group.

1/29Nächste Seite


Current issue

All issues


All videos

Product of the week


Stock list

All quotes


  • THERAMETRICS (CH)0.06 CHF20.00%
  • PROTHENA PLC (IE)49.54 USD9.14%
  • BIOFRONTERA (D)2.27 EUR7.08%


  • BAVARIAN NORDIC (D)35.60 EUR-8.48%


  • CHRONTECH PHARMA (S)0.38 SEK3700.0%
  • THROMBOGENICS (B)3.84 EUR34.7%
  • OREXO (S)60.75 SEK22.2%


  • TRANSGENE (F)2.64 EUR-45.3%
  • GALAPAGOS (B)36.57 EUR-28.9%


  • KARO BIO (S)45.50 SEK4740.4%
  • CHRONTECH PHARMA (S)0.38 SEK375.0%
  • VERONA PHARMA (UK)4.55 GBP237.0%


  • NEOVACS (F)0.69 EUR-80.5%
  • BIOTEST (D)17.90 EUR-77.1%

No liability assumed, Date: 03.10.2015


All Events